The education library

Oxymetholone (Anadrol): anaemia research, medical history and risks

Educational information, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review has been completed. This library is associated with a supplies store; it does not sell steroids or provide instructions for nonmedical use.

Identity and medical history

Oxymetholone is the generic name associated with Anadrol. The archived US label describes it as both anabolic and androgenic and identifies certain anaemias caused by deficient red-cell production as its medical indication. That is more specific than saying it treats all anaemia: different causes require different assessment and treatment. The label reviewed here dates from 2004 and does not establish present market availability. Archived Anadrol label, FDA, 2004

Its medical history is closely connected with bone-marrow failure. An important question when reading that history is whether an improvement in blood counts also improved survival, symptoms or the need for other treatment. Those outcomes should be reported separately rather than compressed into a single claim that the medicine “worked.”

What the human anaemia evidence shows

A randomized study in 134 people with acquired aplastic anaemia compared an immunosuppressive treatment programme with or without oxymetholone. At 120 days, the response rate was 56% with the added androgen and 40% without it. Early mortality was approximately 17% in each arm. This supports a blood-response finding within that older treatment programme; it does not show an early survival advantage.

The distinction matters for patients and families. A response is valuable, but it is not identical to a cure. The study also cannot establish the best treatment today, when alternatives, supportive care and patient selection may differ. EBMT Severe Aplastic Anaemia Working Party randomized trial, 1993

Another randomized aplastic-anaemia trial included oxymetholone in both groups and varied the corticosteroid component. Such a design cannot isolate the effect of oxymetholone itself. Counting every paper containing the drug's name as independent proof of its effectiveness would therefore be misleading. Prospective randomized aplastic-anaemia trial, 1992

Pharmacology: explaining a response is not proving a cure

Researchers have investigated how oxymetholone affects blood-forming cells. A Fanconi-anaemia mouse study found improved blood measurements and increased proliferation of blood stem and progenitor cells. Changes in osteopontin expression were proposed as part of the mechanism. With chronic exposure, the researchers also observed stem-cell exhaustion in a competitive-repopulation experiment.

This is mechanistic animal evidence. It helps formulate questions about benefit and durability, but it cannot supply a human risk percentage or establish that the same process occurs to the same degree in patients. A responsible explanation preserves both the interesting biological finding and that limit. Zhang and colleagues, Stem Cell Reports, 2015

Research beyond anaemia

A placebo-controlled trial randomly assigned 43 haemodialysis patients and assessed body composition, grip strength and muscle measurements over 24 weeks. Oxymetholone was associated with greater gains in fat-free mass and handgrip strength and a reduction in fat mass. Liver enzymes also rose, and the investigators concluded that the intervention induced liver injury.

The results illustrate a clinical trade-off rather than a recommendation for general muscle gain. These participants had kidney failure and were receiving dialysis. A change in grip strength in that setting is not evidence of improved athletic performance or long-term safety in healthy people. The small trial also cannot reliably settle uncommon harms. Effect of oral anabolic steroid on muscle strength and muscle growth in haemodialysis patients

Metabolic measurements in dialysis

A separate published randomized study of 44 dialysis patients reported changes in an insulin-resistance index and body composition over 24 weeks. Two treated patients developed elevated liver enzymes. An insulin-resistance index is an intermediate measurement; it does not demonstrate prevention of diabetes, fewer cardiovascular events or longer life. The relationship between this study's participants and other dialysis publications must be checked before treating the reports as fully independent confirmation. Randomized haemodialysis insulin-sensitivity study, 2009

HIV-associated wasting

An older randomized placebo-controlled trial enrolled 89 adults with HIV-associated wasting. Over the blinded period, the active-treatment groups gained roughly 3–3.5 kg compared with about 1 kg in the placebo group. Some body-cell-mass and reported wellbeing outcomes also improved. However, substantial liver-enzyme increases occurred in the active groups, with liver toxicity identified as the major adverse event.

It would be incomplete to cite the weight change while leaving out the toxicity. This study also belongs to an earlier HIV-treatment era and does not establish a current treatment recommendation. Weight change in illness-associated wasting is a different clinical question from changing appearance in someone without that illness. Hengge and colleagues, AIDS, 2003

Liver risk: laboratory changes and structural disease

The liver concerns are not limited to a mildly abnormal blood test. A published case report described two patients with Fanconi anaemia who developed hepatic abnormalities and tumours after prolonged oxymetholone treatment. The report described tumour regression after marrow transplantation allowed androgen withdrawal.

A two-patient report cannot estimate incidence, and Fanconi anaemia itself creates a complicated disease context. Nevertheless, it documents a serious clinical signal that should not be erased by reassuring anecdotes or an absence of symptoms. Case reports and randomized trials answer different questions: the former can alert clinicians to unusual harm, while the latter can compare selected outcomes under controlled conditions. Regression of androgen-related hepatic tumours following marrow transplantation, 1984

Other organ systems and populations needing caution

The archived label warns about adverse cholesterol changes, fluid retention, reproductive-hormone suppression and potentially irreversible virilization. Pregnancy exposure can harm a fetus. It also lists severe liver dysfunction and certain kidney and cancer conditions among contraindications. These warnings require individual clinical interpretation; a person's prior tolerance does not establish that future exposure is safe. Archived Anadrol label, 2004

Interactions

The label identifies clinically important interactions with warfarin and other oral anticoagulants, possible changes in diabetes-medicine requirements, and increased fluid-retention concerns with adrenal steroids or ACTH. Readers should not attempt to compensate by changing another medicine themselves. Archived Anadrol label, 2004

Closer look at the dialysis trial

The full dialysis report confirms a small, selected trial: 43 participants were randomized and 41 completed follow-up. One treated participant was removed after altered liver function. People with diabetes and several serious comorbidities were excluded. These exclusions and withdrawals matter when interpreting the favourable muscle outcomes; the results cannot establish safety for all dialysis patients or healthy readers. Full trial methods and patient flow

Canadian context

Oxymetholone is specifically listed under anabolic steroids and their derivatives in Schedule IV of Canada's Controlled Drugs and Substances Act. That classification is not a product approval or an indication that a named brand is currently available. Department of Justice, Schedule IV

A publication from the Canadian Inherited Marrow Failure Registry was identified during this review. It reports patients treated with oxymetholone or danazol. Its complete results have not yet been checked, so this article does not use it to claim a Canadian response rate or present-day standard of care. Research performed in Canada and authorization of a particular medicine are separate questions. Canadian registry publication, 2020 — further review pending

Questions that improve the discussion

When a medical claim sounds convincing, ask what condition was studied, what the comparison was and which outcome improved. Ask whether the reported benefit came with adverse effects, whether other treatments were given, and whether the finding still informs current care. These questions allow a balanced account of oxymetholone's medical role without turning historical evidence into a general endorsement.

Scope and limitations

Current Canadian product authorization has not been established here. Historical labels and foreign approvals are identified as such. Some evidence was checked at abstract level; where full results were unavailable, no additional findings are inferred. The article is not a current treatment guideline or a complete account of all possible adverse effects.